NCT00515619View on ClinicalTrials.gov

Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

PHASE3CompletedINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Epilepsy
Interventions
DRUG

Lacosamide

50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial

Trial Locations (54)

35039

Marburg

Unknown

Randwick

Maroochydore

Woodville

Clayton

Parkville

West Heidelberg

Adelaide

Zagreb

Brno

Hradec Králové

Olomouc

Ostrava-Trebovice

Pilsen

Prague

Helsinki

Kuopio

Oulu

Tampere

Lille

Lyon

Montpellier

Paris

Toulouse

Berlin

Erlangen

Göttingen

München

Ulm

Budapest

Pécs

Szeged

Szombathely

Kaunas

Vilnius

Bialystok

Gdansk

Krakow

Warsaw

Moscow

Saint Petersburg

Girona

Granada

Madrid

Zaragoza

Gothenburg

Linköping

Stockholm

Cardiff

Dundee

Glasgow

London

Salford

Swansea

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT00515619 - Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures | Biotech Hunter | Biotech Hunter